NN 5501Alternative Names: NN5501
Latest Information Update: 16 Jan 2008
At a glance
- Originator Novo Nordisk
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 16 Jan 2008 Discontinued - Preclinical for Type-2 diabetes mellitus in Denmark (unspecified route)
- 16 Jan 2008 Discontinued - Preclinical for Type-1 diabetes mellitus in Denmark (unspecified route)
- 16 Apr 1999 New profile